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CSSi003-A (2961)Inlternative name(s) of
stem cell lineCOL04 clE2DstitutionC
ECellular Reprogramming Unit, IRCCS Casa Sollievo
della Sofferenza – Viale dei Cappuccini, 71013 San
Giovanni Rotondo, Foggia, Italyontact information of
distributorJessica ROSATI j.rosati@css-mendel.itpe of cell line iPSC
rigin Human
dditional origin info Age:37
Sex: Female
Ethnicity: Caucasian/Italianell source Dermal fibroblasts
lonality Clonal
ethod of
reprogrammingNon integrating episomal vectorsenetic modification NO
pe of modification N/A
ssociated disease Smith-Magenis syndrome.rosati@css-mendel.it (J. Rosati).
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expressed in the brain, suggesting a central role in brain function. The
production of iPSC carrying a RAI1 haploinsufficiency will allow us to
study the mutated gene's pathological influence on brain development
and function.
Resource details
The hallmarks of Smith-Magenis syndrome (OMIM # 182290)
are sleep disturbances, multiple developmental anomalies,p://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Fig. 1 panel B
Phenotype Immunocytochemisty
qRT-PCR
Staining of pluripotency markers: Oct4; Tra-1-60.
Expression of pluripotency markers: OCT4, LIN28, L-MYC, KLF4, SOX2
Fig. 1 panel E, F
Flow cytometry N/A
Genotype Karyotype
(G-banding) and
resolution
46 XX,
Resolution 450–500
Fig. 1 panel D
Identity Microsatellite PCR
(mPCR)
N/A
STR analysis 19 sites (D13S252, D13S305, D13S634, D13S800, D13S628, D18S819, D18S535, D18S978, D18S386, D18S390,
D21S11, D21S1437, D21S1409, D21S1442, D21S1435, D21S1446, DXS6803, XHPRT, DXS1187): all matched
Data available
with the authors
Mutation analysis (if
applicable)
Sequencing heterozygous NM_030665.3:c.1194del Fig. 1 panel C
Southern Blot OR WGS N/A
Microbiology and
virology
Mycoplasma Mycoplasma tested by N-Garde Mycoplasma PCR kit (EuroClone): Negative Supplementary
Fig. 1
Differentiation
potential
In vitro: embryoid
body formation
In vivo: teratoma
formation
Genes expressed in embryod bodies: SOX1, NESTIN, PAX6, EOMES, T, GATA4, FOXA2, SOX 17.
Proof of three germ layers formation.
Fig. 1 panel I
Fig. 1 panel H
Donor screening
(optional)
HIV 1+2 Hepatitis B,
Hepatitis C
N/A
Genotype additional
info (optional)
Blood group
genotyping
N/A
HLA tissue typing N/A
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(Chen et al., 2015). The incidence of SMS is estimated at 1:25000 births,
although this value may be underreported, and no gender differences
have been observed (Elsea andGirirajan, 2008).RAI1 gene, the causative
gene of SMS, contains six exonswhich generate an ~8.5-kbmRNA and a
1906-amino-acid nuclear protein (Carmona-Mora et al., 2012). Rai1
protein has transcriptional factor activity, however little is known
about its role. We collected skin fibroblasts (Fig. 1A) from a patient car-
rying the novel mutation NM_030665.3:c.1194delC, which generates a
truncated form of RAI1 protein. We reprogrammed SMS fibroblasts
into iPSCs, using non-integrative episomal vectors containing the
reprogramming factors OCT4, SOX2, L-MYC, KLF4, LIN28, shp53. We
characterized the clones with ES-like morphology (Fig. 1B). Genomic
DNA sequencing has been performed andwe have verified that the dis-
ease-related mutation (NM_030665.3:c.1194delC) was retained in the
iPSCs (Fig. 1C). Moreover, we confirmed that, after more than twenty
passages, the SMS iPSCs line displayed a normal karyotype (46, XX)
(Fig. 1D). We analyzed the expression of the surface marker TRA-1-60
and the transcription factor OCT4 through immunofluorescence analy-
sis (Fig. 1E): TRA-1-60 protein is present in cell surfaces and OCT4 pro-
tein is evident in the nuclear compartment of the iPS cells. We also
verified the presence of endogenous expression of the pluripotency
markers, LIN28, SOX2, OCT4 and L-MYC using qPCR (Fig. 1F). After ten
passages of amplification, we confirmed the suppression of exogenous
reprogramming factor expression to negligible levels by qPCR using
primers against episomal sequences flanking the exogenous genes;
the positive control is constituted by fibroblasts collected at 24 h from
episomal nucleofection (Fig. 1G). Pluripotency capacity of the SMS
iPSCswas tested differentiating the iPSC both in vitro through embryoid
bodies assay (Fig. 1I) and in vivo through a teratoma assay. All three
germ layers: ectodermal, mesodermal and endodermal were present
in the teratoma, as demonstrated by immune-histochemical analysis
(Fig. 1H). We demonstrated a high expression of the markers of each
germ layer through qPCR (Fig. 1L). Short tandem repeats analysisFig. 1. Characterization of SMS iPSC. A. Smith-Magenis patient-derived skin fibroblast cell
chromatograms of mutated RAI1 gene in SMS fibroblasts (upper panel) and SMS iPSC
Immunofluorescence staining shows expression of pluripotency markers OCT3/4 (green) an
100 μm. F. qRT-PCR analysis for pluripotent markers. The experiment was repeated twice in
This experiment was repeated twice in triplicate using different cDNAs. H. Histological sectio
in suspension. Scale bar, 100 μm. L. qRT-PCR analyses of all three germ layer markers from SM
prepared cDNAs.(STR) showed that the DNA profile of the donor's fibroblasts was iden-
tical to the derived iPSCs (data available with the authors). All cells
tested negative for Mycoplasma contamination (Supplementary file
1). These data demonstrate thatwe have successfully generated a stable
SMS patient specific iPSCs line useful for studying the Smith-Magenis
disorder, at the molecular level (Table 1).
Materials and methods
Skin biopsy and fibroblast reprogramming
Skin fragmentswere cut into small fragments and plated on a tissue-
culture dish in Dulbecco's Modified Eagle Medium (DMEM) High Glu-
cose supplemented with 20% FBS, 2 mM L-Glutamine, 100 U/ml Penicil-
lin-Streptomicin and 1× Non-Essential Amino Acids (Sigma Aldrich)
and cultured for 30 days to allow fibroblasts to grow.
Approximately 1 × 105 fibroblasts were nucleofected with a mix of
three pCXLE-based episomal vectors: pCXLE-hOCT4-shp53, pCXLE-
hUL and pCXLE-hSK (Addgene). After nucleofection, cells were cultured
for 6 days in fibroblastsmedium. On day 7, cells were plated onMatrigel
(Corning) coated plates in NutristemXFmedium (Biological Industries).
The emergent hiPSC colonies were expanded under feeder-free condi-
tions. Absence of mycoplasma contamination was verified using N-
Garde Mycoplasma PCR kit (EuroClone).
q-PCR
Total RNAs were isolated using TRIzol reagent (Life Technologies).
cDNAwas synthesized using High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems). qPCR was performed using SYBR Green
primers for pluripotency markers and TaqMan primers for differentia-
tion markers (Table 2). Each reaction was performed in triplicate with
β-ACTIN gene as reference. 2–ΔΔCT method was adopted to calculate
the relative expression levels.line. Scale bar, 100 μm. B. iPSC colonies morphology. Scale bar, 100 μm. C. Sequencing
(lower panel): the box indicates the mutation site. D. normal iPSC karyogram. E.
d TRA-1-60 (red) in SMS iPSC. Cell nuclei were stained with HOECHST (blue). Scale bar,
triplicate using three cDNAs. G. qRT-PCR analysis for transgenes transcripts in SMS iPSC.
ns of teratoma derived from SMS iPSC, stained with hematoxylin and eosin. I. COL04 EBs
S embryoid bodies. This experiment was repeated twice in triplicate using independently
Table 2
Antibodies used for immunocytochemistry/flow-cytometry.
Antibody Dilution Company Cat # and
RRID
Pluripotency markers Rabbit anti-OCT4
Mouse anti-TRA-1-60
1:100
1:100
Life technologies (A13998)
Life technologies (411000)
Secondary antibodies Anti-rabbit AlexaFluor 488
Anti-mouse AlexaFluor 555
1:10000
1:10000
Invitrogen (A11034)
Invitrogen (A21422)
Sybr Green primers
used for qPCR
Target Forward/reverse sequence (5′-3′)
Exogenous episomal
genes
eOCT4 Fwd: CAT TCA AAC TGA GGT AAG GG
Rev: TAG CGT AAA AGG AGC AAC ATA G
eKLF4 Fwd: CCA CCT CGC CTT ACA CAT GAA GA
Rev: TAG CGT AAA AGG AGC AAC ATA G
eLIN28 Fwd: AGC CAT ATG GTA GCC TCA TGT CCG C
Rev: TAG CGT AAA AGG AGC AAC ATA G
eL-MYC Fwd: GGC TGA GAA GAG GAT GGC TAC
Rev: TTT GTT TGA CAG GAG CGA CAA T
eSOX2 Fwd: TTC ACA TGT CCC AGC ACT ACC AGA
Rev: TTT GTT TGA CAG GAG CGA CAA T
Pluripotency markers OCT4 Fwd: CCC CAG GGC CCC ATT TTG GTA CC
Rev: ACC TCA GTT TGA ATG CAT GGG AGA GC
LIN28 Fwd: AGC CAT ATG GTA GCC TCA TGT CCG C
Rev: TCA ATT CTG TGC CTC CGG GAG CAG GGT AGG
L-MYC Fwd: GCG AAC CCA AGA CCC AGG CCT GCT CC
Rev: CAG GGG GTC TGC TCG CAC CGT GAT G
SOX2 Fwd: TTC ACA TGT CCC AGC ACT ACC AGA
Rev: TCA CAT GTG TGA GAG GGG CAG TGT GC
House-keeping gene β-ACTIN Fwd: GGC ATC CTC ACC CTG AAG TA
Rev: GGG GTG TTG AAG GTC TCA AA
TaqMan primers used for qPCR Target Probe
Differentiation markers SOX1 Hs01057642_s1
NESTIN Hs04187831_g1
PAX6 Hs00240871_m1
T Hs00610080_m1
EOMES Hs00172872_m1
GATA4 Hs00171403_m1
FOXA2 Hs00232764_m1
SOX17 Hs00751752_s1
β-ACTIN Hs 99999903_m1
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Mechanically-detached iPSCs were plated in a Petri dish in floating
condition. Nutristem-XF medium was then switched with DMEM F-
12, 20% Knock-out serum replacement (Gibco), 0.1 mM β-
mercaptoethanol, 1× NEAA, 50 U/ml Penicillin-Streptomicin, 2 mM L-
glutamine in 3 days. EBs were grown in suspension for 14 days.
Immunofluorescence staining
Cellswere fixed using 4% paraformaldehyde for 20min at room tem-
perature and the blocked in PBS containing 20%Normal Goat Serum and
0.1% Triton X-100 for 30 min at room temperature. Next, primaryantibodies, listed in Table 2, diluted in blocking buffer were added and
incubated O/N at 4 °C. After extensive washing, Alexa-Fluor-conjugated
secondary antibodies were added for 1 h at room temperature. Cellular
nuclei were counterstained with Hoechst. Microphotograps were taken
using a Nikon C2 fluorescence microscope.
Teratoma formation
Approximately 3 × 106 Dispase-treated iPSC were resuspended in
100 μl of Matrigel. Cells were injected into immune-deficient mice, fol-
lowing ethical guidelines. Teratomas formed in 4–8 weeks. Upon re-
moval, tumors were histologically analyzed to check for their in vivo
differentiation capacity into derivatives of all three germ layers.
Karyotype analysis
Cells were treated with a 0.1 μg/ml COLCEMID solution (Thermo
Fisher Scientific) for 60 min at 37 °C. Metaphases were obtained by
adding 30 mM KCl in 10% FBS at 37 °C for 6 min and by fixation using
cold fresh-made 3:1 ethanol:acetic acid solution. Karyotype analysis was
carried out on GTG-banded metaphases. Fifteen metaphases were
counted and three karyotypes analyzed (450–500 resolution). Only clonal
aberrations were considered, following the ISCN recommendations.
STR analysis
Fibroblasts and iPSCs DNA was extracted by Dneasy blood and tissue
kit (QIAGEN) following manufacturer's suggestions. PCR amplification of
19 distinct STRs (D13S252, D13S305, D13S634, D13S800, D13S628,
D18S819, D18S535, D18S978, D18S386, D18S390, D21S11, D21S1437,
D21S1409, D21S1442, D21S1435, D21S1446, DXS6803, XHPRT,
DXS1187)was carried out using the QST*Rplusv2 kit (Elucigene Diagnos-
tics), PCR products were separated on an ABI Prism 3130 DNA sequencer
and analyzed by GeneMapper version 4.0 (Applied Biosystems).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2018.02.016.
Acknowledgment
This work was supported by grants from the Italian Ministry of
Health: Ricerca Corrente 2017 to JR.
References
Carmona-Mora, P., Canales, C.P., Cao, L., Perez, I.C., Srivastava, A.K., Young, J.I., Walz, K.,
2012. RAI1 transcription factor activity is impaired in mutants associated with
Smith-Magenis syndrome. PLoS One 7 (9), e45155.
Chen, L., Mullegama, S.V., Alaimo, J.T., Elsea, S.H., 2015. Smith-Magenis syndrome and its
circadian influence on development, behavior, and obesity - own experience. Dev.
Period Med. 19 (2), 149–156 (Review).
Elsea, S.H., Girirajan, S., 2008. Smith-Magenis syndrome. Eur. J. Hum. Genet. 16 (4),
412–421.
